论文部分内容阅读
目的：观察基因工程人白细胞介素Ⅱ（rIL-2）注射剂治疗恶性胸腔积液的疗效。方法：对29例癌性胸水患者用rIL-2做胸腔内注射给药，每周1～2次，2～4周为一疗程，全组平均注射3次，4次注射无效即停药；对照组23例用DDP做胸腔内注射以做比较。结果：治疗组29例患者总有效率为82．76％（24／29），胸水癌细胞转阴率为79．2％（19／29）；对照组总有效率82．6％（19／23），胸水癌细胞转阴率89．7％（17／23）。结论：rIL-2对癌性胸水患者有治疗效果，具有与化疗药物相近的控制胸水的作用，且毒副反应小，患者易于接受。
Objective: To observe the efficacy of genetically engineered human interleukin-2 (rIL-2) injection in the treatment of malignant pleural effusions. METHODS: Twenty-nine patients with cancerous pleural effusion were treated with intrapleural injection of rIL-2, one or two times a week for 2 to 4 weeks as a course of treatment. The average injection was 3 times in the whole group, and 4 injections were stopped. The control group received intrathoracic injections of DDP for comparison. Results: The total effective rate of 29 patients in the treatment group was 82.76% (24/29), and the conversion rate of pleural effusion cancer cells was 79.2% (19/29); the total effective rate in the control group was 82.6% (19/ 23) The conversion rate of pleural effusion cancer cells was 89.7% (17/23). Conclusion: rIL-2 has therapeutic effect on patients with cancerous pleural effusion. It has the similar effect of controlling pleural effusion with chemotherapeutic drugs, and has little side effects and is easily accepted by patients.